A major technical challenge in advancing therapies for Retinitis Pigmentosa (RP) is developing efficient and safe drug delivery systems that can get the therapeutic agent—whether it is a gene, an ASO, or a neuroprotective drug—to the target cells in the retina. The eye's natural defenses and the tight junction barrier in the retina make it difficult for many compounds to penetrate from the bloodstream or even from a simple eye drop.

Current advanced therapies primarily rely on injection into the eye, either subretinally (under the retina) for gene replacement to target photoreceptors or intravitreally (into the eye's center) for broader delivery of ASOs and neuroprotective agents. Innovation is now focused on improving the efficiency of these vectors, such as engineering new AAV serotypes (like AAV2 7m8) with enhanced tropism to target photoreceptors more effectively following a less invasive intravitreal injection. This reduces the need for complex subretinal surgery.

The successful development of superior, less invasive delivery methods that minimize the necessary drug dose and reduce surgical risk is crucial for expanding treatment accessibility globally. The ongoing quest for highly efficient vector systems and non-viral delivery methods ensures that the drug delivery technology segment remains a key area of technical advancement in the Retinitis Pigmentosa Treatment Market field.

FAQ 1: What is the difference between subretinal and intravitreal injection for RP? Subretinal injection places the drug directly under the retina, which is highly effective for targeting photoreceptors but is surgically invasive; intravitreal injection is simpler but less efficient for targeting the back of the eye.

FAQ 2: Why is improving drug delivery so important for RP therapies? It is important because the retina is protected by barriers that make it difficult for drugs to reach the affected cells, and improved delivery reduces surgical risks and increases the efficacy of the treatment.